Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Share this content:
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.

Title: ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma1

Principal Investigator: Eric Bernicker, MD, Houston Methodist Cancer Center

Description: For this open-label phase 2 study (ClinicalTrials.gov Identifier: NCT02831933), researchers are evaluating whether patients with metastatic non–small cell lung cancer (NSCLC) will benefit from stereotactic body radiation (SBRT) and a virally mediated gene therapy prior to nivolumab.

The gene therapy injections will contain “adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk).” Patients will also receive valacyclovir, an antiviral used to treat HSV.

Patients will receive ADV/HSV-tk on day 0, valacyclovir from days 1 through 15, SBRT from days 2 through 16, and nivolumab 240 mg started day 17.

The primary outcome is overall response rate; secondary outcomes include duration of response, overall survival, and progression-free survival.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02831933.

Status: This study is open and recruiting patients as of December 15, 2017.

This study is sponsored by Eric Bernicker, MD.

Reference

  1. Clinicaltrials.gov. Trial of stereotactic body radiation and gene therapy before nivolumab for metastatic non-small cell lung carcinoma (ENSIGN). NCT02831933. https://clinicaltrials.gov/ct2/show/NCT02831933. Accessed December 15, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs